Literature DB >> 3928684

Anti-Fab antibodies in humans. Predominance of minor immunoglobulin G subclasses in rheumatoid arthritis.

J E Persselin, R H Stevens.   

Abstract

Isoelectric focusing analyses of sera from patients with rheumatoid arthritis (RA) demonstrate two populations of antibodies directed against the Fab portion of pooled human IgG. One population is composed of polyclonal alkaline anti-Fab antibodies (alpha FABA) and the other, acidic alpha FABA which are more clonally restricted. In this study we have identified the immunoglobulin classes and subclasses of these antibodies in RA sera. Enzyme-linked immunosorbent assays (ELISA) demonstrated alpha FABA in RA sera to be predominantly IgG. A large portion of IgG alpha FABA existed as immune complexes, inasmuch as dialysis of RA sera against 6 M urea before ELISA analysis was necessary for maximal detection of alpha FABA activity. Chromatofocusing of RA sera isolated alpha FABA of different charges and revealed the acidic clonally restricted alpha FABA to be IgG4 and IgG3, whereas the polyclonal alkaline group contained IgG1, IgG2, and IgG3. Overall, acidic IgG3 and IgG4 comprised 70% of IgG alpha FABA, and high levels of IgG4 were seen in most RA sera. When alpha FABA were elevated in normal sera, they were primarily of the IgG4 subclass, and also existed as immune complexes. Serum anti-Fab activity was removed by adsorption of sera with Fab fragments. Anti-Fab antibodies of both kappa and lambda light-chain types were present in RA sera, and F(ab')2 fragments of RA serum immunoglobulin were found to possess anti-Fab activity. These studies indicate that alpha FABA in RA sera are limited to the IgG class, and that most of these antibodies exist as immune complexes and display clonal and minor IgG subclass restriction.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3928684      PMCID: PMC423887          DOI: 10.1172/JCI112027

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  32 in total

1.  1958 Revision of diagnostic criteria for rheumatoid arthritis.

Authors:  M W ROPES; G A BENNETT; S COBB; R JACOX; R A JESSAR
Journal:  Bull Rheum Dis       Date:  1958-12

Review 2.  The immunopathology of joint inflammation in rheumatoid arthritis.

Authors:  N J Zvaifler
Journal:  Adv Immunol       Date:  1973       Impact factor: 3.543

3.  Immunglobulin classes, subclasses and complexes of IgG rheumatoid factor in rheumatoid plasma cells.

Authors:  E Munthe; J B Natvig
Journal:  Clin Exp Immunol       Date:  1972-09       Impact factor: 4.330

Review 4.  Chemistry and reaction mechanisms of complement.

Authors:  H J Müller-Eberhard
Journal:  Adv Immunol       Date:  1968       Impact factor: 3.543

5.  Antibodies in human sera to F(ab')2 fragments of monoclonal and polyclonal IgG.

Authors:  N R Ling; P Drysdale
Journal:  Int Arch Allergy Appl Immunol       Date:  1981

6.  Presence of auto-anti-idiotypic antibody during the normal human immune response to tetanus toxoid antigen.

Authors:  R S Geha
Journal:  J Immunol       Date:  1982-07       Impact factor: 5.422

7.  Gamma globulin complexes in synovial fluids of patients with rheumatoid arthritis. Partial characterization and relationship to lowered complement levels.

Authors:  R J Winchester; V Agnello; H G Kunkel
Journal:  Clin Exp Immunol       Date:  1970-05       Impact factor: 4.330

8.  Physiology and pathology of rheumatoid factors.

Authors:  D A Carson; J L Pasquali; C D Tsoukas; S Fong; S F Slovin; S K Lawrance; L Slaughter; J H Vaughan
Journal:  Springer Semin Immunopathol       Date:  1981

9.  IgG antiglobulins in rheumatoid arthritis and other arthritides: relationship with clinical features and other parameters.

Authors:  C Allen; C J Elson; D G Scott; P A Bacon; R C Bucknall
Journal:  Ann Rheum Dis       Date:  1981-04       Impact factor: 19.103

10.  Anti-Fab' antibodies in rheumatoid arthritis. Measurement of the relative quantities incorporated in soluble immune complexes in sera and supernatants from cultured peripheral blood lymphocytes.

Authors:  H H Birdsall; M D Lidsky; R D Rossen
Journal:  Arthritis Rheum       Date:  1983-12
View more
  12 in total

1.  Anti-F(ab')2 antibodies in thrombocytopenic patients at risk for acquired immunodeficiency syndrome.

Authors:  J R Yu; E T Lennette; S Karpatkin
Journal:  J Clin Invest       Date:  1986-06       Impact factor: 14.808

Review 2.  Beyond citrullination: other post-translational protein modifications in rheumatoid arthritis.

Authors:  Leendert A Trouw; Theo Rispens; Rene E M Toes
Journal:  Nat Rev Rheumatol       Date:  2017-03-09       Impact factor: 20.543

3.  The in vitro resistance of IgG2 to proteolytic attack concurs with a comparative paucity of autoantibodies against peptide analogs of the IgG2 hinge.

Authors:  Randall J Brezski; Allison Oberholtzer; Brandy Strake; Robert E Jordan
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

4.  Human IgG anti-F(ab')2 antibodies possess rheumatoid factor activity.

Authors:  S Hunt Gerardo; J E Persselin; R H Stevens
Journal:  Clin Exp Immunol       Date:  1990-08       Impact factor: 4.330

Review 5.  Cleavage of IgGs by proteases associated with invasive diseases: an evasion tactic against host immunity?

Authors:  Randall J Brezski; Robert E Jordan
Journal:  MAbs       Date:  2010-05-23       Impact factor: 5.857

6.  IgG binding of monoclonal anti-nuclear antibodies from MRL-lpr/lpr mice.

Authors:  D S Pisetsky; B S Darwin; C F Reich
Journal:  Immunology       Date:  1990-12       Impact factor: 7.397

7.  Serum IgG4 anti-Fab antibodies in rheumatoid arthritis are constitutively expressed.

Authors:  J E Persselin; R H Stevens
Journal:  Rheumatol Int       Date:  1988       Impact factor: 2.631

8.  Platelet surface IgG in patients receiving infusions of Fab fragments of a chimaeric monoclonal antibody to glycoprotein IIb-IIIa.

Authors:  C Christopoulos
Journal:  Clin Exp Immunol       Date:  1994-10       Impact factor: 4.330

9.  Distribution of anti-F(ab')2 antibodies and the 16/6 idiotype in systemic lupus erythematosus (SLE) probands and kindreds.

Authors:  F Silvestris; R A Searles; R C Williams; M A Rodriguez; R S Schwartz
Journal:  J Clin Immunol       Date:  1989-11       Impact factor: 8.317

10.  Cholestatic liver disease after rituximab and adalimumab and the possible role of cross-reacting antibodies to Fab 2 fragments.

Authors:  Joerg Latus; Reinhild Klein; Ina Koetter; Matthias Schwab; Peter Fritz; Martin Kimmel; M Dominik Alscher; Niko Braun
Journal:  PLoS One       Date:  2013-11-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.